- Trial phase
- Approved
- Time to market
- Already approved and marketed since July 2015
- Why 4/10
- Praluent is already FDA-approved and marketed with no pending PDUFA date or pivotal readout scheduled in the next ~12 months. The last major label expansion (pediatric HeFH) was in March 2024, and the Amgen patent litigation was settled in March 2026. ImpactScore is capped at 4 under the rubric: approved drug with no imminent binary catalyst, and a small contributor (under 1%) to Regeneron's ~$14.3B annual revenue.
Praluent is a mature, marketed product that is unlikely to drive material share-price moves for REGN on its own. Investors should instead focus on Regeneron's much larger value drivers: Dupixent (the biggest growth engine), EYLEA HD (eye disease), and the broader pipeline. The key risk to watch for Praluent specifically is biosimilar entry as key patents expire, but even disruption there would be a rounding error for REGN's top line.
Price Chart
Executive Summary
Praluent (generic: alirocumab) is an injectable PCSK9 inhibitor cholesterol drug co-developed by Regeneron (NASDAQ: REGN) and Sanofi (SNY). It was the first PCSK9 inhibitor approved in the US (July 2015) and now carries indications for cardiovascular risk reduction, primary hyperlipidemia (including heterozygous and homozygous familial hypercholesterolemia), and pediatric HeFH (ages 8+). Despite being a first-in-class drug, Praluent is a distant #2 behind Amgen's Repatha, which commands about twice the prescription volume. For Regeneron, Praluent is a minor revenue contributor, US net product sales of roughly $57M-$72M per quarter, representing well under 1% of the company's $14.3B in 2025 total revenue. With no imminent regulatory catalysts and looming biosimilar competition as patents expire, Praluent is a low-impact asset for REGN shareholders.
How It Works
Praluent is a monoclonal antibody (a lab-made immune protein) that blocks a specific enzyme called PCSK9. Normally, PCSK9 destroys the "docking stations" on liver cells that remove bad cholesterol (LDL) from the bloodstream. By blocking PCSK9, Praluent preserves more docking stations, allowing the liver to clear more LDL cholesterol out of the blood, lowering cholesterol levels and reducing the risk of heart attacks and strokes.
Trial Status
Praluent has been FDA-approved since July 2015. The label has been expanded multiple times since: in 2019 to include cardiovascular outcomes (heart attack/stroke risk reduction), in 2021 for homozygous familial hypercholesterolemia (HoFH), and in March 2024 for pediatric patients aged 8+ with heterozygous familial hypercholesterolemia (HeFH). No further pivotal trials or regulatory decisions are pending.
The Two-Sided Case
Upcoming Catalysts
- No near-term binary catalysts for Praluent specifically, drug is already fully approved and marketed
- Biosimilar entry timelines as patents expire (first US patent expirations reportedly around 2025)
- Quarterly earnings disclosures, Praluent US sales are reported as a line item in Regeneron's quarterly earnings (next: Q2 2026 results)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report